CatalYm was founded by Jörg Wischhusen.

Who are CatalYm's investors?

CatalYm's investors include Jeito Capital, Bioqube Ventures, Forbion, Bayern Kapital, BioGeneration Ventures, Canaan Partners, coparion, Novartis Venture Fund and 1 more.

How much funding has CatalYm raised?

CatalYm has disclosed $300M raised across 2 of its 3 known rounds.

Where is CatalYm headquartered?

CatalYm is headquartered in Munich, DE.

CatalYm

Munich, DE · 56 employees on LinkedIn · 11 known investors

Find your way into CatalYm

Each arrow is one introduction. Sign up to fill in the first one.

113 people can intro you to Stefan

Ask Ward Capoen to introduce you to Stefan Ries

You →Ward · together at Sibylla →Stefan

27 people can intro you to Sujata

Ask Jamie Chen to introduce you to Sujata Rao

You →Jamie · together at Insilico Medicine →Sujata

17 people can intro you to Andrea

Ask Sam Okafor to introduce you to Andrea Goddard

You →Sam · together at Prolific Machines →Andrea

Your email: who you already know at CatalYm, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the CatalYm team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment. Its lead antibody, visugromab, is being advanced through clinical trials in combination with anti-PD-1 therapies to overcome cancer therapy resistance.

Biotech Deep Tech Healthtech

Founders & leadership

Jörg WischhusenScientific Co-founder

Scott ClarkeChief Executive Officer

Peter GarciaChief Financial Officer

Sujata Rao Chief Medical OfficerSujata Rao is a medical oncologist with over 17 years in biotechnology and clinical development who completed a fellowship at Memorial Sloan-Kettering Cancer Center; she brings expertise in immune oncology and medical affairs to her role as Chief Medical Officer at CatalYm.

Stefan Ries Chief Scientific Officer and Head of Munich SiteStefan Ries has over 20 years of experience in oncology drug development across small molecules, biologics, and cellular therapies in roles at major pharmaceutical companies, venture capital firms, and biotech startups. He serves as Chief Scientific Officer and Head of the Munich Site at CatalYm.

Andrea Goddard Chief Technical OfficerAndrea Goddard is Chief Technical Officer at CatalYm and brings three decades of biotechnology manufacturing, process development, and quality leadership, spanning roles from production floor through executive positions overseeing teams across multiple countries.

Investors · 11

Jeito Capital✓ confirmed by CatalYmParis

How we know: the company's own site · Jeito Capital's portfolio page · Not right? Tell us

Bioqube Ventures✓ confirmed by CatalYmBrussels · $108K – $6.5M

How we know: the company's own site · funding news · Not right? Tell us

Forbion✓ confirmed by CatalYmNaarden

How we know: the company's own site · globenewswire.com · Not right? Tell us

Bayern Kapitallisted by Bayern KapitalLandshut · $275K – $55M

How we know: Bayern Kapital's portfolio page · a partner's Signal profile · Not right? Tell us

BioGeneration Ventureslisted by BioGeneration VenturesNaarden

How we know: BioGeneration Ventures's portfolio page · a partner's Signal profile · globenewswire.com · the VCSheet dataset · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

coparionlisted by coparionCologne · $550K – $16.5M

How we know: coparion's portfolio page · globenewswire.com · Not right? Tell us

Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · globenewswire.com · Not right? Tell us

Red Tree VenturereportedSan Diego

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 2

Vesalius Biocapital IIIleadWachstumsfonds Bayern

Funding

SEC filings, press & company announcements

$300M disclosed across 2 of 3 rounds · 2020–2024

$150MSeries DJul 2024 · 2 sources
Source ↗
$150MraisedJul 2024 · 3 sources
Source ↗
Undisclosed amountSeries BNov 2020
Vesalius Biocapital III (lead), BioGeneration Ventures, coparion, Forbion, Novartis Venture Fund, Wachstumsfonds Bayern
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through CatalYm went on to found or lead other companies.

Pascal TouchonMember Board of DirectorsFounded Atara Biotherapeutics Phil L'HuillierChief Executive OfficerFounded Scancell Holdings Plc

In the news

CatalYm Raises $150M in Series D Fundingfinsmes.com · Jul 2024

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patientsglobenewswire.com · Nov 2020

Frequently asked questions

What does CatalYm do?: CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment. Its lead antibody, visugromab, is being advanced through clinical trials in combination with anti-PD-1 therapies to overcome cancer therapy resistance.
Who founded CatalYm?: CatalYm was founded by Jörg Wischhusen.
Who are CatalYm's investors?: CatalYm's investors include Jeito Capital, Bioqube Ventures, Forbion, Bayern Kapital, BioGeneration Ventures, Canaan Partners, coparion, Novartis Venture Fund and 1 more.
How much funding has CatalYm raised?: CatalYm has disclosed $300M raised across 2 of its 3 known rounds.
Where is CatalYm headquartered?: CatalYm is headquartered in Munich, DE.